申请人:Pfizer Inc
公开号:US05559129A1
公开(公告)日:1996-09-24
Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, X and n are as defined in the claims and the pharmaceutically acceptable salts thereof are new. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting hypertensives and vasodilators. A process for forming indoles by transition metal catalyzed cyclization of dihalogenated intermediate is also disclosed.
该公式化合物 ##STR1## 中,其中R.sub.1、R.sub.2、R.sub.3、X和n如权利要求中所定义,以及其药用可接受盐是新的。这些化合物是有用的精神治疗药物,是有效的血清素(5-HT.sub.1)激动剂,可用于治疗抑郁症、焦虑症、进食障碍、肥胖症、药物滥用、集簇头痛、偏头痛、疼痛、慢性阵发性半头痛和与血管疾病相关的头痛,以及其他由血清素神经递质缺乏引起的疾病。这些化合物还可用作中枢作用降压药和扩血管剂。还公开了通过过渡金属催化的二卤代中间体环化形成吲哚的方法。